Women's Health
FDA Approves Pancreatic Cancer Pill That Nearly Doubles Survival Time
The FDA approved Rasonque (daraxonrasib), a first-in-class daily pill that nearly doubled survival for metastatic pancreatic cancer patients in a 500-person trial.
By Elliot O·Aug 27, 2026
Originally reported by MindBodyGreen.
The FDA approved Rasonque (daraxonrasib), a first-in-class daily pill that nearly doubled survival for metastatic pancreatic cancer patients in a 500-person trial.
Filed Under
Women's HealthMindBodyGreenHealth & Fitness
